

Webinar PAIS and butyrate


How to treat low butyrate-producing capacity

13-4-2026

Koosje Janssen, Dennis Zeilstra

Conclusions

1. Butyrate is a bacterial metabolite that is key for our health
2. It has both local and systemic effects
3. Levels are very low in PAIS patients
4. Low levels can be treated with several approaches



1. Kalkan, A. E. et al. *Nutrients*.17.,1305.(2025)

Three approaches to treat low butyrate


1



Prebiotic fibers



1 Prebiotics: substrate for butyrate production by commensals




- Short chain fatty acid (SCFA) types¹:
 - Acetate (most abundant: 60%)
 - Propionate (20%)
 - Butyrate (20%)
- Produced by fermentation of fibers and sugars
- The number of taxa that exhibit the enzymatic capabilities is very different per pathway

1. Parada Venegas, D. et al. *Front. Immunol.* 10., (2019)
 2. Van-Wehle, T. et al. *npj Biofilms Microbiomes.* 10., 63. (2024)

1 Prebiotics: substrate for butyrate production by commensals

- Pathways¹:
 - Butyrate: 2 main pathways
 - Propionate: 3 pathways, 2 main
 - Acetate: 2 main pathways



1. Ríos-Covián, D. et al. Front Microbiol. 7:185 (2016)

1

Prebiotics: not all fibers are equal (1/2)





Fig. 2. SCFA proportions for acetate, propionate, butyrate and other (isobutyrate, isovalerate, valerate and caproate), as a proportion of total SCFA concentrations, across fibres investigated following fermentation. Values shown represent the mean SCFA proportions across three replicate experiments conducted using samples provided by three independent participants. Differences between fibres were evaluated using one-way ANOVA. * Significant differences ($P < 0.05$; Fisher's least significant difference) between fibres and the blank control for acetate and butyrate proportions. XOS, xylo-oligosaccharide. □, Butyrate; ■, acetate; ■, propionate; ■, other.

1. So, D. et al. British Journal of Nutrition. 126, 208–218. (2021)


1

Prebiotics: not all fibers are equal (2/2)




1. Fehlbaum, S. et al. IJMS.19,.3097.(2018)

1 Prebiotics: effects are person-specific^{1,2}



1. Teichmann, J. et al. *Front. Microbiol.* 12, (2021)
2. Simonelli, N. et al. *Food Bioscience.* 62, 105329. (2024)

1 Prebiotics: reasons for differences: composition individual, pathways vary per taxa



1. Reichardt, N. et al. The ISME Journal. (2017)

1 Prebiotics: PHGG is good butyrate stimulator




FIG. 4. Butyric acid production from various sources.

Example case 1

IBS and low butyrate
producers



Case low butyrate formers

Julia, 1978

- Chronic gastrointestinal complaints existing for about 4 years consistent with an irritable bowel with predominantly diarrhea (IBS-D)
- Pronounced fatigue / reduced load capacity
- Lactose intolerance confirmed by lactose breath test
- Strict lactose restriction, but persistent symptoms despite this
- Colonoscopy without abnormalities (exclusion of structural intestinal pathology)

Voorgeschiedenis:



- Emergency section with scarring 2012, appendectomy

Leefstijl / voeding:

- Predominantly whole, vegetable-rich food, little fruit, no soft drinks/alcohol
- Physical activity, endurance athlete

Microbioome analysis july 2024:

Case low butyrate formers



Case low butyrate formers

Test	Ergebnis	Einheit	Normbereich	Vorwert
Proteus spp.	< 1,0 x 10 ⁶	KBE/g Stuhl	< 1,0 x 10 ⁶	
Klebsiella spp.	< 1,0 x 10 ⁶	KBE/g Stuhl	< 1,0 x 10 ⁷	
Enterobacter spp.	< 1,0 x 10 ⁶	KBE/g Stuhl	< 1,0 x 10 ⁶	
Serratia spp.	< 1,0 x 10 ⁶	KBE/g Stuhl	< 1,0 x 10 ⁷	
Haefia spp.	< 1,0 x 10 ⁶	KBE/g Stuhl	< 1,0 x 10 ⁶	
Morganella spp.	< 1,0 x 10 ⁶	KBE/g Stuhl	< 1,0 x 10 ⁶	
Citrobacter spp.	< 1,0 x 10 ⁶	KBE/g Stuhl	< 5,0 x 10 ⁶	
Pseudomonas spp.	7,2 x 10 ⁶	KBE/g Stuhl	< 5,0 x 10 ⁷	
Providencia spp.	< 1,0 x 10 ⁶	KBE/g Stuhl	< 5,0 x 10 ⁷	
H2S-Bildung				
Sulfid-reduzierende Bakterien	2,9 x 10 ¹⁰	KBE/g Stuhl	< 2,5 x 10 ⁹	
Desulfovibrio piger	< 1,0 x 10 ⁶	KBE/g Stuhl	< 1,0 x 10 ⁹	
Desulfomonas pigra	< 1,0 x 10 ⁶	KBE/g Stuhl	< 1,0 x 10 ⁹	
Bifidobacterium	< 1,0 x 10 ⁶	KBE/g Stuhl	< 2,0 x 10 ⁸	
Immunogenität/Ausprägung				
Immunogen wirkende Bakterien:				
Escherichia coli	7,8 x 10 ⁹	KBE/g Stuhl	10 ⁶ - 10 ⁷	
Enterococcus spp.	3,61 x 10 ⁶	KBE/g Stuhl	10 ⁶ - 10 ⁷	
Lactobacillus spp.	4,3 x 10 ⁵	KBE/g Stuhl	10 ⁹ - 10 ¹²	
Milchbildung/Schleimhautantigen				
Akkermansia muciniphila	< 1,0 x 10 ⁶	KBE/g Stuhl	> 5,0 x 10 ⁶	
Faecalibacterium prausnitzii	1,4 x 10 ¹⁰	KBE/g Stuhl	> 1,0 x 10 ¹¹	
Archaea				
Methanogene				
Methanobrevibacter spp.	< 1,0 x 10 ⁶	KBE/g Stuhl	< 5,0 x 10 ⁸	
<small>ACHTUNG: Das neue OncoRep-Kit misst und die darin enthaltenen Marker ermöglichen einen noch erhöhten Proteindruck, vor allem bei den grampositiven Bakterien. Dadurch ergeben sich leichte Verschiebungen in den Normbereichen. Wir bitten die zu berücksichtigen.</small>				
Mykozoen: relevante Hefen				
Candida albicans (CA)	< 1,0 x 10 ³	KBE/g Stuhl	< 1,0 x 10 ³	
Candida krusei (CK)	< 1,0 x 10 ³	KBE/g Stuhl	< 1,0 x 10 ³	
Candida glabrata (CG)	< 1,0 x 10 ³	KBE/g Stuhl	< 1,0 x 10 ³	
Candida dubliniensis (CD)	< 1,0 x 10 ³	KBE/g Stuhl	< 1,0 x 10 ³	
Candida parapsilosis (CP)	< 1,0 x 10 ³	KBE/g Stuhl	< 1,0 x 10 ³	
Candida tropicalis (CT)	< 1,0 x 10 ³	KBE/g Stuhl	< 1,0 x 10 ³	
Candida lusitanae (CL)	< 1,0 x 10 ³	KBE/g Stuhl	< 1,0 x 10 ³	
Maldigestion, Malabsorption, MIS				
Verdauungsparameter				
Quant. Nachweis von Fett	3,52	g/100g	< 3,8	
Quant. Nachweis von Stickstoff	0,49	g/100g	< 1,0	
Quant. Nachweis von Zucker	4,01	g/100g	< 2,5	
Quant. Nachweis von Wasser	79,32	g/100g	75 - 85	
Nachweis einer Maldigestion				
Pankreaselastase im Stuhl	526,12	µg/g	> 200	
Gallensäuren im Stuhl	21,82	µmol/l	< 7,5	

Test	Ergebnis	Einheit	Normbereich	Vorwert	Probematerial Methode
Nachweis einer Malabsorption					
Calprotectin	31,00	mg/l	< 50		FE A) ELISA
Alpha 1-Antitrypsin	8,8	mg/dl	< 27,5		FE A) ELISA
Einzelparameter					
Sekretorisches Immunglobulin A (sIgA)	195,0	µg/ml	510 - 2040		FE A) ELISA

Case low butyrate formers

Therapy:

- Based on microbiological stool analysis started with an individual therapy with MyOwnBlend for 8 weeks
- In addition, manual treatment of the cesarean scar, control and replenishment of micronutrients

Course:

- After about 6 weeks a severe flu-like infection, according to patient more serious than before At that time increased psychological strain, but already physical stabilization of the intestinal complaints
- Another 8 weeks of MyOwnBlend for further stabilization

Rezept Datum: 05-10-2024

	Pro Tag (gramm)	Gesamt (gramm)
MyOwnBlend, Magistral-Preparat 2 Monaten (oral)		
PHGG	6	360
L. plantarum P-8	2	120
Bifidobacterium lactis HN019	3	180
Lactiplantibacillus plantarum DR7	2	120
Bacillus coagulans Unique IS-2	1	60
Akkermansia muciniphila, pasteurisiertes	1	60
Gesamt	15	900

Case low butyrate formers

Results:

- November 2024 no more diarrhoea complaints
- Increase in energy and load capacity (marathon in 2025)


Current status:

- Significantly improved overall condition
- Good gastrointestinal stability
- In view of the enormous progress, patient and practitioner have chosen not to do a retest

Butyrate in PAIS




Long COVID and Dysbiosis: reduced butyrate producers



Lau RI, Su Q, Ng SC. Long COVID and gut microbiome: insights into pathogenesis and therapeutics. *Gut Microbes*. 2025

Long COVID: low SCFAs


Production of SCFA is low in Long-Covid



Fen Zhang et al., Prolonged Impairment of Short-Chain Fatty Acid and L-Isoleucine Biosynthesis in Gut Microbiome in Patients With COVID-19. *Gastroenterology*


ME/CFS: low SCFAs¹

Myalgic Encephalomyelitis / Chronic Fatigue Syndrome



1. Guo, C. et al. Cell Host & Microbe. 31, 288-304.e8. (2023)

NB: butyrate protects against severe infectious disease¹



1. Kullberg, R. F. J. et al. *The Lancet Microbe*.5.,(2024)

1



Prebiotic fibers

2

Ecosystem-supporting
probiotics




3


Butyrate-producing
probiotics



Butyrate




2 Influence the microbiome ecosystem to boost butyrate production



Various mechanisms indirectly influence butyrate production, including via¹:

- Cross-feeding
- Production and excretion of vitamins and other nutrients
- Changing composition of microbiome via competition, bacteriocins, network effects, etc.




1,2-PDO: 1,2-Propanediol

1. van Deuren, T. et al. *Obesity Reviews*.n/a.,e13498.(2022)
2. Belzer, C. et al. *mBio* 8, e00770-17 (2017)

2 Influence the microbiome ecosystem *Bifidobacterium adolescentis* SH001



***B. adolescentis* is known cross-feeder for *F. prausnitzii*
(most abundant butyrate producer in our gut)¹**




1. Rios-Covian, D. et al. FEMS Microbiology Letters. 362, fmv176. (2015)

2 Influence the microbiome ecosystem *Bifidobacterium longum* ES1




***B. Longum* ES1** also increases *F. prausnitzii*, but not (only) as cross-feeder, since it was heat-killed (i.e. postbiotic) in this study¹. This shows how **modulation of the ecosystem** can boost butyrate-production



1. Naghibi, M. et al. *Nutrients*.16.,3952.(2024)

2 Influence the microbiome ecosystem the many actions of probiotics



1. Khalighi, A. et al. in Probiotics and Prebiotics in Human Nutrition and Health. (IntechOpen, 2016)

2

Influence the microbiome ecosystem *Saccharomyces boulardii* CNCM-I-1079




Fig. 1 Cure rate for clinical findings and parasitological examinations between study groups on the 14th day and first month





Figure 1 | Primary outcome: Effect of *Saccharomyces boulardii* (SB) on *Helicobacter pylori* eradication rates.



Inhibits parasites (*Entameba histolytica*, *Blastocystis hominis*, *Giardia lamblia*)¹⁻³

Inhibits *Helicobacter pylori*⁴

Anti-inflammatory and intestinal barrier function-enhancing effects^{5,6}

- Dinleyici, E. C. et al. Am. J. Trop. Med. Hyg. 80, 953–955 (2009)
- Dinleyici, E. C. et al. Parasitol. Res. 108, 541–545 (2011)
- Besirbellioglu, B. A. et al. Scandinavian Journal of Infectious Diseases 38, 479–481 (2006)
- Szajewska, H. et al. Alimentary Pharmacology & Therapeutics 41, 1237–1245 (2015)
- Abbas, Z. et al. European Journal of Gastroenterology & Hepatology 1 (2014)

- Garcia Vilela, E. et al. Scandinavian Journal of Gastroenterology. 43, 842–848. (2008)

The contents of this document are property of Microbiome Center and are classified as confidential. Neither the document, nor parts thereof may be published, reproduced, copied, made public, or distributed without explicit written permission of Microbiome Center. This content shall not be considered medical advice and is provided for information purpose only. The content is exclusively intended for health care professionals.

Example case 2

Crohn's disease and low
butyrate producers



Case Crohn's disease and low butyrate formers





Guido, 2011

- Crohn's with very high calprotectin, many complaints
- Since 3 years of joint inflammation, CRP increased, juvenile rheumatism was first thought.
- Nauseous, no appetite, lost 10 kilos in the past 3 months
- Def: diarrhea, lots of undigested remains
- Low energy, no focus, can't exercise
- Biologicals started but insufficient effect

- Microbiome analysis February 2025

Case Crohn's disease a



The contents of this document are property of the Microbiome Center and may be published, reproduced, copied, made public or otherwise used for information purposes only. The content is exclusively intended for health care professionals.

Case Crohn's disease and low butyrate formers

Test	Uitlag	Eenheid	Nommerk	Volg onderzoek
<i>Proteus</i> spp.	< 1,0 x 10 ⁶	KVEig feces	< 1,0 x 10 ⁶	
<i>Klebsiella</i> spp.	< 1,0 x 10 ⁶	KVEig feces	< 1,0 x 10 ⁷	
<i>Enterobacter</i> spp.	7,4 x 10 ⁷	KVEig feces	< 1,0 x 10 ⁶	
<i>Serratia</i> spp.	3,7 x 10 ⁷	KVEig feces	< 1,0 x 10 ⁷	
<i>Haflnia</i> spp.	< 1,0 x 10 ⁶	KVEig feces	< 1,0 x 10 ⁶	
<i>Morganella</i> spp.	< 1,0 x 10 ⁶	KVEig feces	< 1,0 x 10 ⁶	
<i>Citrobacter</i> spp.	< 1,0 x 10 ⁶	KVEig feces	< 5,0 x 10 ⁶	
<i>Pseudomonas</i> spp.	< 1,0 x 10 ⁶	KVEig feces	< 5,0 x 10 ⁷	
<i>Providencia</i> spp.	< 1,0 x 10 ⁶	KVEig feces	< 5,0 x 10 ⁷	
H2S-voeding				
Sulfatireducerende bacteriën (SRB)	< 1,0 x 10 ⁶	KVEig feces	< 2,5 x 10 ⁶	
Desulfotribio pipe	< 1,0 x 10 ⁶	KVEig feces	< 1,0 x 10 ⁶	
<i>Desulfomonas</i> pigra	< 1,0 x 10 ⁶	KVEig feces	< 1,0 x 10 ⁶	
<i>Blifhila wadsworthia</i>	< 1,0 x 10 ⁶	KVEig feces	< 2,5 x 10 ⁶	
Immunogeniteit / mucine voeding				
Immunogen werkzame bacteriën				
<i>Escherichia coli</i>	4,5 x 10 ⁶	KVEig feces	10 ⁶ - 10 ⁷	
<i>Enterococcus</i> spp.	4,42 x 10 ⁶	KVEig feces	10 ⁶ - 10 ⁷	
<i>Lactobacillus</i> spp.	1,6 x 10 ⁶	KVEig feces	10 ⁵ - 10 ⁷	
Mucine voeding / slijmbevatende				
<i>Akkermansia muciniphila</i>	< 1,0 x 10 ⁶	KVEig feces	> 5 x 10 ⁶	
<i>Faecalibacterium prauenzii</i>	< 1,0 x 10 ⁶	KVEig feces	> 1,0 x 10 ¹¹	
Archeën				
Methanogenen				
<i>Methanobrevibacter</i> spp.	< 1,0 x 10 ⁶	KVEig feces	< 5,0 x 10 ⁶	
Opmerking: Het nieuwe Orisdiap-buikje en de laatste samenstelling meten niet een nog effectievere monstervorming mogelijk, vooral bij grampositieve bacteriën. Dit resulteert in lagere detectiesgrenzen in de nommeren. We vragen u hier rekening mee te houden.				
Mycobiota: relevante gisten				
<i>Candida albicans</i> (CA)	< 1,0 x 10 ³	KVEig feces	< 1,0 x 10 ³	
<i>Candida krusei</i> (CK)	< 1,0 x 10 ³	KVEig feces	< 1,0 x 10 ³	
<i>Candida glabrata</i> (CG)	< 1,0 x 10 ³	KVEig feces	< 1,0 x 10 ³	
<i>Candida dubliniensis</i> (CD)	< 1,0 x 10 ³	KVEig feces	< 1,0 x 10 ³	
<i>Candida parapsilosis</i> (CP)	< 1,0 x 10 ³	KVEig feces	< 1,0 x 10 ³	
<i>Candida tropicalis</i> (CTp)	< 1,0 x 10 ³	KVEig feces	< 1,0 x 10 ³	
<i>Candida lusitanae</i> (CL)	< 1,0 x 10 ³	KVEig feces	< 1,0 x 10 ³	
Parasieten				
Pathobionten				
<i>Blastocystis hominis</i>	negatief		negatief	
<i>Dientamoeba fragilis</i>	negatief		negatief	
Pathogene darmprotozoa				
<i>Giardia lamblia</i>	negatief		negatief	
<i>Entamoeba histolytica</i>	negatief		negatief	
<i>Cryptosporidium</i> spp.	negatief		negatief	

Test	Uitlag	Eenheid	Nommerk	Volg onderzoek
<i>Cyclospora cayentanensis</i>	negatief		negatief	
Vertoring				
Vetgehalte	7,20	g/100g	< 3,5	
Stikstofgehalte	0,40	g/100g	< 1,0	
Suikergehalte	5,80	g/100g	< 2,5	
Watergehalte	78,80	g/100g	75 - 85	
Extra parameter(s)				
Calprotectine	>800,00	mg/l	< 50	
Alfa-1-antitripsine	44,9	mg/dl	< 27,5	
Secretair Immunoglobuline A	4582,3	µg/ml	510 - 2040	
Zonuline	91,25	ng/ml	< 55	

property of Microbiome Center and are classified as confidential. Neither the document, nor parts thereof may be made public, or distributed without explicit written permission of Microbiome Center. This content shall not be provided for information purpose only. The content is exclusively intended for health care professionals.

Case Crohn's disease and low butyrate formers



MyOwnBlend

Code	Element	Dagdosering
M002	MyOwnBlend, magistrale bereiding 2 maanden (oraal)	
BB021	Bacillus coagulans Unique IS-2	2
BB061	Bifidobacterium lactis HN019	2
BB022	Enterococcus faecium + Bacillus subtilis	1
BB028	L. plantarum P-8	1
BB027	L. rhamnosus SP1	1
BB075	Lactiseibacillus paracasei Lpc-37	1
BB029	PHGG	5
BB058	S. Boulardii CNCM-I-1079	2

Case Crohn's disease and low butyrate formers




- **Result**

- Feb-July: have not been sick anymore, stools more stable and more energy, gained weight
- July epididymitis requiring antibiotics, after which again dysregulation
- Started school in Sept, went well, started phasing out biologicals on my own initiative and MOB was finished

- **Follow-up:**


- Nov stool restless again, energy still good
- Restart biologicals and MOB after which improvement again
- Retest January 2026

Case Crohn's disease



The contents of this document are pro-
 be published, reproduced, copied, and
 considered medical advice and is p


Case Crohn's disease and low butyrate formers



The contents of this document are property of Microbiome Center and are classified as confidential. Neither the document, nor parts thereof may be published, reproduced, copied, made public, or distributed without explicit written permission of Microbiome Center. This content shall not be considered medical advice and is provided for information purpose only. The content is exclusively intended for health care professionals.

Butyrate



Health effects




Butyrate metabolism and systemic health effects



INTESTINAL FATE (MAJORITY USE)




SYSTEMIC HEALTH EFFECTS (MINORITY CIRCULATION)




1. McNabney, S. M. et al. *Nutrients*.9.,1348.(2017)
2. Singh, V. et al. *Front. Microbiol.*13.,1103836.(2023)
3. Hays, K. E. et al. *Gut Microbes*.16.,2393270.(2024)

Butyrate local health effects



Litvak, Y. et al. *Science*.362.,eaat9076.(2018)

Butyrate systemic health effects



van Deuren, T. et al. Obesity Reviews. n/a, e13498. (2022)


1



Prebiotic fibers

2

Ecosystem-supporting probiotics



Butyrate-producing probiotics

3





Butyrate

3

Butyrate-producing probiotics: “Butyrate generator”



- This building block contains three strains:
 - Enterococcus faecium* T-110
 - Clostridium butyricum* TO-A
 - Bacillus subtilis* TO-A
- On the Japanese market as medicine since 1963
- Strains act symbiotically, yielding *in situ* butyrate production of *C. butyricum*
- Butyrate** has strong anti-inflammatory properties¹⁻³
 - Exemplified by effect of this building block on ulcerative colitis⁴⁻⁶
- For this building block there is also evidence for:
 - Anti-inflammatory effects^{4,7,8}
 - Infectious diarrhea^{7,8}
- Data analysis: favorable effect in patients with allergy.
- Typical use: inflammation with low butyrate-producing capacity.





- Brahe, L. K. et al. *Obesity Reviews* 14, 950–959 (2013)
- Chang, P. V. et al. *PNAS* 111, 2247–2252 (2014)
- Stoeva, M. K. et al. *Gut Microbes* 13, 1907272 (2021)
- Yoshimatsu, Y. et al. *World J Gastroenterol* 21, 5985–5994 (2015)
- Tsuda, Y. et al. *Scand. J. Gastroenterol.* 42, 1306–1311 (2007)
- Lee, J. et al. *Gastroenterology Research and Practice* 2022, 1–5 (2022)
- Chen, C.-C. et al. *Pediatr. Infect. Dis. J.* 29, 135–138 (2010)
- Huang, Y.-F. et al. *J. Clin. Gastroenterol.* 48, 37–42 (2014)
- Aisu, N. et al. *Experimental and Therapeutic Medicine* 10, 966–972 (2015)

The contents of this document are property of Microbiome Center and are classified as confidential. Neither the document, nor parts thereof may be published, reproduced, copied, made public, or distributed without explicit written permission of Microbiome Center.

3

Butyrate-producing probiotics: “Butyrate generator” (Bio-three)



3 Butyrate-producing probiotics: Synergy between *C. butyricum* and PHGG





Figure 2. Synergistic effect of different prebiotic dietary fiber supplementation as a carbon source on *Clostridium butyricum* bacterial stain for enhanced butyrate production during in-vitro fermentation. (a) bacterial growth (OD₆₆₀), (b) variation in pH of basal medium, and (c) butyrate production. [Statistical significance: p ≤ 0.05]

1. Matsumiya, Y. et al. Functional Foods in Health and Disease - Online ISSN: 2160-3855; Print ISSN: 2378-7007.14,.455-469.(2024)

3 Butyrate-producing probiotics to come: *Christensenella minuta* Lx-03

HEALTH EFFECTS OF *CHRISTENSENELLA MINUTA*: A NEXT-GENERATION PROBIOTIC



Example case 3

UTI and low butyrate
producers



Case UTIs and low butyrate formers



Amber, 1996

- Recurrent UTIs, past 2 years also pyelonephritis, often antibiotics (including probiotics)
- History:
 - Lyme for which different treatments abroad
 - Endometriosis
 - Sinus Tachycardia
- Fam: many autoimmune diseases
- Def: daily, sometimes diarrhea, very bloated and bulging belly.
- Nutrition: been working on it for 12 years, had a holistic natural dietitian, she is clear what she can and cannot eat. Also did an IgG test. Hypersensitive to gluten and milk protein.

- Microbiome analysis Augustus 2024

Case UTIs and low butyrate fo

ome



The contents of this document are property of Microbiome Center and are published, reproduced, copied, made public, or distributed without our considered medical advice and is provided for information purpose o

Case UTIs and low butyrate formers

Test	Uitslag	Eenheid	Normbereik	Vorig onderzoek
Proteus spp.	< 1,0 x 10 ⁴ 5	KVE/lg feces	= 1,0 x 10 ⁶	FE
Klebsiella spp.	1,0 x 10⁴10	KVE/lg feces	= 1,0 x 10 ⁷	FE
Enterobacter spp.	< 1,0 x 10 ⁴ 5	KVE/lg feces	= 1,0 x 10 ⁶	FE
Serratia spp.	< 1,0 x 10 ⁴ 5	KVE/lg feces	= 1,0 x 10 ⁷	FE
Hafnia spp.	< 1,0 x 10 ⁴ 5	KVE/lg feces	= 1,0 x 10 ⁶	FE
Morganella spp.	4,1 x 10⁴7	KVE/lg feces	= 1,0 x 10 ⁶	FE
Citrobacter spp.	4,0 x 10 ⁴ 8	KVE/lg feces	= 5,0 x 10 ⁶	FE
Pseudomonas spp.	< 1,0 x 10 ⁴ 5	KVE/lg feces	= 5,0 x 10 ⁷	FE
Providencia spp.	< 1,0 x 10 ⁴ 5	KVE/lg feces	= 6,0 x 10 ⁷	FE
H2S-voeding				
Sulfreducerende bacteriën (SRB)	8,8 x 10⁹9	KVE/lg feces	= 2,0 x 10 ⁹	FE
Desulfotomobacter piger	< 1,0 x 10 ⁴ 5	KVE/lg feces	= 1,0 x 10 ⁹	FE
Desulfomonas pigra	< 1,0 x 10 ⁴ 5	KVE/lg feces	= 1,0 x 10 ⁹	FE
Biophila wadiaeworthii	< 1,0 x 10 ⁴ 5	KVE/lg feces	= 2,0 x 10 ⁹	FE
Immunogerijsel / muisne vorming				
Immunogeen werkende bacteriën				
Escherichia coli	3,8 x 10⁴8	KVE/lg feces	10 ⁶ - 10 ⁷	FE
Enterococcus spp.	8,34 x 10 ⁴ 6	KVE/lg feces	10 ⁶ - 10 ⁷	FE
Lactobacillus spp.	1,5 x 10⁴5	KVE/lg feces	10 ⁶ - 10 ⁷	FE
Muisne vorming / afrijfbaarheids				
Akkermansia muciniphila	< 1,0 x 10 ⁴ 5	KVE/lg feces	= 5,0 x 10 ⁹	FE
Faecalibacterium prausnitzii	< 1,0 x 10 ⁴ 5	KVE/lg feces	> 1,0 x 10 ¹¹	FE
Archaen				
Methanogenen				
Methanobrevibacter spp.	< 1,0 x 10 ⁴ 5	KVE/lg feces	= 5,0 x 10 ⁶	FE
Opmerking: Het reusere OntoStap-buide en de daarin aanwezige muisne maken een nog effectievere monstervanalyse mogelijk, vooral bij grampositieve bacteriën. Dit resulteert in lichtere verhoudingen in de normbereiken. We vragen u hier rekening mee te houden.				
Mycobloom: niet-vante gisten				
Candida albicans (CA)	< 1,0 x 10 ⁴ 3	KVE/lg feces	= 1,0 x 10 ³	FE
Candida krusei (CK)	< 1,0 x 10 ⁴ 3	KVE/lg feces	= 1,0 x 10 ³	FE
Candida glabrata (CG)	< 1,0 x 10 ⁴ 3	KVE/lg feces	= 1,0 x 10 ³	FE
Candida dubliniensis (CD)	< 1,0 x 10 ⁴ 3	KVE/lg feces	= 1,0 x 10 ³	FE
Candida parapsilosis (CP)	< 1,0 x 10 ⁴ 3	KVE/lg feces	= 1,0 x 10 ³	FE
Candida tropicalis (CTp)	< 1,0 x 10 ⁴ 3	KVE/lg feces	= 1,0 x 10 ³	FE
Candida lusitanae (CL)	< 1,0 x 10 ⁴ 3	KVE/lg feces	= 1,0 x 10 ³	FE
Parasieten				
Pathobionten				
Blastocystis hominis	negatief		negatief	FE
Dientamoeba fragilis	negatief		negatief	FE
Pathogene darmprotoczoen				
Giardia lamblia	negatief		negatief	FE
Entamoeba histolytica	negatief		negatief	FE
Cryptosporidium spp.	negatief		negatief	FE

Test	Uitslag	Eenheid	Normbereik	Vorig onderzoek
Cyclospora cayentanensis	negatief		negatief	FE
Vertoring				
Vetgehalte	5,10	g/100g	< 3,5	FE
Stikstofgehalte	0,60	g/100g	< 1,0	FE
Suikergehalte	4,70	g/100g	< 2,5	FE
Watergehalte	79,10	g/100g	75 - 85	FE
Extra parameter(s)				
Calprotectine	21,50	mg/l	< 50	FE
Alfa-1-antitripsine	17,0	mg/dl	< 27,5	FE
Secretoir Immunoglobuline A	520,2	µg/ml	510 - 2040	FE
Zonuline	93,74	ng/ml	< 55	FE

erty of Microbiome Center and are classified as confidential. Neither the document, nor parts thereof may be public, or distributed without explicit written permission of Microbiome Center. This content shall not be rovided for information purpose only. The content is exclusively intended for health care professionals.

Case UTIs and low butyrate formers

MyOwnBlend

DJrepair, iberis complex

MyOwnBlend, magistrale bereiding onderhoudsrecept (oraal)	
2'-Fucosyllactose	3
Bacillus clausii UBBC-07	1
Butyraat generator	2
L. fermentum ME-3	2
L. rhamnosus GG	2
PHGG	4
S. Boulardii CNCM-I-1079	1

Case UTIs and low butyrate formers


Result:

- No more bladder infections, is very happy with that.
- Bloating belly is almost gone, sometimes still a little in cycle.
- Final: good and stable.
- Nutrition not adjusted, was already good.

Follow-up:

- MOB maintenance recipe (DJ repair no longer necessary)
- Retest April 2026

Case UTIs and low butyrate formers



Test	Uitslag	Eenheid	Nommerk	Vorig onderzoek
Extra parameter(s)				
Calprotectine	22,43	mg/l	< 50	FE AJ ELISA
Alfa-1-antitripsine	11,3	mg/dl	< 27,5	FE AJ ELISA
Secretoir Immunoglobuline A	1116,1	µg/ml	510 - 2040	FE AJ ELISA
Zonuline	194,78	ng/ml	< 55	FE NAJ ELISA

of Microbiome Center and are classified as confidential. Neither the document, nor parts thereof may be public, or distributed without explicit written permission of Microbiome Center. This content shall not be used for information purpose only. The content is exclusively intended for health care professionals.

Summary:

- Butyrate is a bacterial metabolite that is key for our health
- It has both local and systemic effects
- Levels are very low in PAIS patients
- Low levels can be treated with several approaches:
 1. Specific prebiotics/fibers
 2. Influence ecosystem via probiotics
 3. Butyrate-producing probiotics



**Thank you for
your attention!**